Paradigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Paradigm Biocapital Advisors LP raised its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 3.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 4,236,346 shares of the company’s stock after purchasing an additional 150,000 shares during the period. Y-mAbs Therapeutics accounts for about 1.2% of Paradigm Biocapital Advisors LP’s portfolio, making the stock its 22nd largest position. Paradigm Biocapital Advisors LP owned 9.46% of Y-mAbs Therapeutics worth $33,171,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Acorn Capital Advisors LLC purchased a new stake in Y-mAbs Therapeutics in the fourth quarter valued at approximately $22,408,000. Caligan Partners LP boosted its position in shares of Y-mAbs Therapeutics by 47.9% during the 4th quarter. Caligan Partners LP now owns 1,767,982 shares of the company’s stock valued at $13,843,000 after acquiring an additional 572,729 shares during the last quarter. Boothbay Fund Management LLC grew its holdings in shares of Y-mAbs Therapeutics by 24.4% in the fourth quarter. Boothbay Fund Management LLC now owns 693,693 shares of the company’s stock valued at $5,432,000 after purchasing an additional 136,264 shares during the period. Renaissance Technologies LLC grew its stake in shares of Y-mAbs Therapeutics by 371.7% in the 4th quarter. Renaissance Technologies LLC now owns 131,600 shares of the company’s stock valued at $1,030,000 after buying an additional 103,700 shares during the period. Finally, Pictet Asset Management Holding SA grew its position in Y-mAbs Therapeutics by 9.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 756,297 shares of the company’s stock worth $5,922,000 after acquiring an additional 68,317 shares during the period. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Trading Up 2.2%

YMAB stock opened at $4.16 on Wednesday. The company has a market cap of $188.35 million, a PE ratio of -7.70 and a beta of 0.53. The stock has a 50-day moving average price of $4.53 and a two-hundred day moving average price of $7.28. Y-mAbs Therapeutics, Inc. has a 12-month low of $3.76 and a 12-month high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $20.90 million during the quarter, compared to the consensus estimate of $19.97 million. Equities analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the sale, the insider now owns 202,721 shares in the company, valued at $1,060,230.83. This represents a 5.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 22.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

YMAB has been the topic of a number of recent analyst reports. Bank of America cut shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a research report on Tuesday, April 22nd. HC Wainwright cut their target price on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Truist Financial cut their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Wedbush restated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Finally, Morgan Stanley dropped their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.40.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.